



CLL SOCIETY

Abbreviations and Acronyms

Acronym	Meaning
ABG	Arterial Blood Gas
AIHA	Autoimmune Hemolytic Anemia
AE	Adverse Event
Alb	Albumin
ALC	Absolute Lymphocyte Count
ALL	Acute Lymphoblastic Leukemia
AML	Acute Myeloid Leukemia
ANC	Absolute Neutrophil Count
ASCO	American Society of Clinical Oncology
ASH	American Society of Hematology
B2M	Beta2-Microglobulin
BCL-2	B-cell lymphoma 2
BCR	B-cell Receptor
BM	Bone Marrow
BMBx	Bone Marrow Biopsy
BMT	Bone Marrow Transplant
BR	Bendamustine and Rituximab
BTK	Bruton's Tyrosine Kinase
BUN	Blood Urea Nitrogen
Ca	Calcium
CAM	Complementary and Alternative Medicine
CAR-T	Chimeric Antigen Receptor T-cell
CBC	Complete Blood Count
CD	Cluster of Differentiation
CIT	Chemo immuno Therapy
CK	Complex Karotype
Cl	Chlorine
CLL	Chronic Lymphocytic Leukemia
CML	Chronic Myeloid Leukemia
CO2	Carbon Dioxide
CP	Convalescent Plasma
Cr	Creatinine
CR	Complete Response
CRS	Cytokine Release Syndrome
Del (17p)	17p Deletion
DFS	Disease Free Survival
DLBCL	Diffuse Large B-Cell Lymphoma

© Copyright 2021 CLL Society, Inc. All Rights Reserved.



CLL SOCIETY

DoR	Duration of Response
Dx	Diagnosis
Dz	Disease
EHA	European Hematology Association
EOT	End of Treatment
FCR	Fludarabine, Cyclophosphamide, Rituximab
FISH	Fluorescence In Situ Hybridization
GVHD	Graft Versus Host Disease
HCT	Hematocrit
HDMP	High dose methyl-prednisolone
HGB	Hemoglobin level
HLA	Human Leukocyte Antigen
HSCT	Hematopoietic Stem Cell Transplant
Hx	History
IAHA	Idiopathic Autoimmune Hemolytic Anemia
Ibr	Ibrutinib
IRC	Independent Review Committee
ITP	Idiopathic (or Immune) Thrombocytopenic Purpura
IwCLL	International Workshop on CLL
K	Potassium
LD	Longest Diameter
LDH	Lactate Dehydrogenase
LDT	Lymphocyte Doubling Time
LN	Lymph Node
MAB	Monoclonal Antibodies
MBL	Monoclonal B-Cell Lymphocytosis
MCH	Mean Corpuscular Hemoglobin
MCHC	Mean Corpuscular Hemoglobin Concentration
MCV	Mean Corpuscular Volume
MDS	Myelodysplastic Syndromes
MPV	Mean Platelet Volume
MRD	Minimal or Measurable Residual Disease
Na	Sodium
NGS	Next Generation Sequencing
O ₂	Oxygen
ORR	Overall Response Rate
OS	Overall Survival
PB	Peripheral Blood
PCR	Polymerase Chain Reaction
PD	Progressive Disease

© Copyright 2021 CLL Society, Inc. All Rights Reserved.



CLL SOCIETY

PFS	Progression Free Survival
PI3K	Phosphoinositide 3-kinase
PLT	Platelets
PR	Partial Response/Partial Remission
Pt	Patient
R	Rituximab
R/R	Relapsed/Refractory
RBC	Red Blood Cell
RCHOP	Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone
RDW	Red cell Distribution Width
RT	Richter's Transformation
SCT	Stem Cell Transplant
SGPT	Serum Glutamic Pyruvic Transaminase
SL	Synthetic Lethality
SLL	Small Lymphocytic Lymphoma
TB4T	Test Before Treat
TBI	Total Body Irradiation
TKI	Tyrosine Kinase Inhibitors
TLS	Tumor Lysis Syndrome
TN	Treatment Naive
TTNT	Time to Next Treatment
TTP	Time to Progression
TTT	Time to Treat
Tx	Treatment
URI	Upper Respiratory Infection
VenR	Venetoclax-Rituximab
Vx	Venetoclax
W&W	Watch and Wait
WBC	White Blood Cells
WM	Waldenstrom's Macroglobulinemia

© Copyright 2021 CLL Society, Inc. All Rights Reserved.